Vor Biopharma Inc.

NasdaqGS:VOR 株式レポート

時価総額:US$54.9m

Vor Biopharma 過去の業績

過去 基準チェック /06

Vor Biopharmaの収益は年平均-30%で減少しているが、Biotechs業界はgrowingで19.3%年平均の収益となった。

主要情報

-30.0%

収益成長率

82.2%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率n/a
株主資本利益率-154.2%
ネット・マージンn/a
前回の決算情報30 Sep 2024

最近の業績更新

更新なし

Recent updates

Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

Sep 10
Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 24
We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Dec 05
Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Aug 18
Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

May 05
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

Mar 13
Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Oct 19
We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Vor Bio appoints Eyal C. Attar as chief medical officer

Oct 12

Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Jun 18
Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Mar 05
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Aug 30
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma: Targeted Therapies For Transplants

Jun 30

We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 10
We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Vor Biopharma EPS misses by $0.03

May 06

収支内訳

Vor Biopharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGS:VOR 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Sep 240-1122989
30 Jun 240-1183095
31 Mar 240-1203197
31 Dec 230-1183294
30 Sep 230-1163290
30 Jun 230-1063280
31 Mar 230-983071
31 Dec 220-922965
30 Sep 220-862760
30 Jun 220-812556
31 Mar 220-782454
31 Dec 210-702148
30 Sep 210-702046
30 Jun 210-651841
31 Mar 210-561534
31 Dec 200-491232
30 Sep 200-36823
30 Jun 200-26717
31 Mar 200-19512
31 Dec 190-1346

質の高い収益: VORは現在利益が出ていません。

利益率の向上: VORは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: VORは利益が出ておらず、過去 5 年間で損失は年間30%の割合で増加しています。

成長の加速: VORの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: VORは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。


株主資本利益率

高いROE: VORは現在利益が出ていないため、自己資本利益率 ( -154.15% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘